Ascorbic Acid

Overview

Ascorbic acid (Vitamin C) is a water-soluble vitamin with antioxidant properties that plays an essential role in collagen synthesis, tissue repair, immune function, and numerous oxidation–reduction reactions. Unlike some species, dogs and cats are capable of synthesizing adequate amounts of vitamin C endogenously and therefore do not have a dietary requirement under normal conditions.

In small animal medicine, ascorbic acid is not routinely supplemented, but it may be used on an extra-label, adjunctive basis in selected clinical situations. These include its use as an antioxidant in cases of toxin-induced oxidative injury or methemoglobinemia, and less commonly as a urinary acidifier, although its efficacy for urine acidification is considered unreliable.

Mechanism of Action (MOA): Ascorbic acid functions primarily as a reducing agent and antioxidant. It neutralizes reactive oxygen species, supports regeneration of other antioxidants, and can facilitate the reduction of methemoglobin to functional hemoglobin. It is also involved in iron metabolism, collagen formation, and maintenance of vascular integrity.

At recommended dosages, ascorbic acid is generally well tolerated in dogs and cats. However, high doses may alter laboratory test results and, in specific disease states (such as copper-associated hepatopathy), may be detrimental. Therefore, supplementation in dogs and cats should be targeted, short-term, and condition-specific rather than routine.

Indications

In dogs and cats, ascorbic acid (vitamin C) is not considered an essential dietary supplement under normal conditions because these species synthesize adequate endogenous amounts. Its use in small animal practice is therefore limited to selected, extra-label, adjunctive indications.

• Adjunctive antioxidant therapy:
  Used as part of multimodal treatment for ingestion of certain toxicants that cause oxidative injury or methemoglobinemia (eg, acetaminophen, phenazopyridine). Its clinical efficacy is variable and should not replace primary antidotal therapy.
• Adjunctive support in oxidative stress:
  May be used short-term in conditions associated with increased oxidative stress, although routine supplementation is not supported by evidence.
• Urinary acidification (rare use):
  Historically used to acidify urine in dogs and cats, but this indication is now rarely recommended due to inconsistent and unreliable effects.

Ascorbic acid is not indicated for routine supplementation in healthy dogs or cats and is no longer recommended for the management of copper-associated hepatopathy due to the potential to exacerbate hepatic oxidative damage.

Dosage (Reference)

In dogs and cats, ascorbic acid (vitamin C) is used extra-label and only as an adjunctive therapy in selected clinical situations. Routine supplementation is not recommended. Oral dosing does not reliably achieve high plasma concentrations, and clinical benefit is variable.

Dog

Cat

Warnings & Precautions

Ascorbic acid (vitamin C) is generally well tolerated at moderate doses; however, high-dose or inappropriate use may lead to clinically relevant adverse effects or interfere with diagnostic testing. In dogs and cats, supplementation should be reserved for specific indications and not used routinely.

• Routine supplementation: Dogs and cats synthesize adequate endogenous vitamin C; routine supplementation is unnecessary and not recommended in healthy animals.
• Copper-associated hepatopathy: Contraindicated in dogs with copper-induced chronic hepatitis, as ascorbic acid may enhance copper-mediated oxidative liver injury.
• Urolithiasis risk: Use cautiously in patients predisposed to calcium oxalate, cystine, or urate urolithiasis; high doses may increase urinary oxalate and uric acid excretion.
• Diabetes mellitus: High-dose therapy may interfere with laboratory testing (eg, urine glucose, serum creatinine) and complicate glycemic monitoring.
• Questionable efficacy: Oral administration does not reliably achieve high plasma concentrations; clinical benefit as an antioxidant in toxin exposure is inconsistent and should not replace established antidotes.
• Formulation excipients: Some injectable or liquid formulations may contain benzyl alcohol; avoid these products in cats due to toxicity risk.
• IV administration: High plasma concentrations are only achieved with IV dosing; administer diluted in appropriate crystalloid fluids and monitor for local or systemic reactions.
• Gastrointestinal tolerance: Large oral doses may cause diarrhea due to osmotic effects and increased intestinal motility.
• Use in pregnancy and lactation: Generally considered safe at moderate doses, but high-dose supplementation should only be used when maternal benefit outweighs potential risk.
• Monitoring: Patients receiving repeated or high-dose therapy should be monitored for GI tolerance, hydration status, and signs of urinary tract disease.

Drug Interactions

Clinically relevant drug interactions with ascorbic acid are uncommon at nutritional or moderate doses. At higher dosages, interactions are primarily related to urine acidification, altered drug absorption, or interference with drug metabolism and laboratory interpretation.

• Aluminum-containing antacids:
  Ascorbic acid may increase gastrointestinal absorption of aluminum; administer doses at least 2 hours apart to reduce this effect.
• Aminoglycosides (e.g., gentamicin):
  Urine acidification may reduce antimicrobial effectiveness in urinary tract infections; monitor clinical response.
• Cyclosporine:
  Concomitant administration may reduce cyclosporine blood concentrations; therapeutic drug monitoring is recommended when used together.
• Iron-containing products:
  Ascorbic acid enhances gastrointestinal absorption of iron salts; use cautiously in patients with iron overload or hepatic disease.
• Estrogens:
  Plasma estrogen concentrations may be increased with concurrent use, potentially enhancing estrogen-related effects.
• Quinidine:
  Urine acidification may increase renal excretion and reduce therapeutic concentrations.
• Deferoxamine:
  May act synergistically to enhance iron removal; however, combined use has been associated with cardiac dysfunction in humans—use cautiously in patients with underlying cardiac disease.

Side Effects & Overdose

Side Effects

At recommended or short-term adjunctive doses, ascorbic acid (vitamin C) is generally well tolerated in dogs and cats. Adverse effects are uncommon and are most often associated with high oral doses or prolonged administration.

• Gastrointestinal upset:
  Diarrhea, soft stools, or abdominal discomfort may occur due to osmotic effects and increased intestinal motility, particularly at high oral doses.
• Urolithiasis risk:
  Chronic or high-dose supplementation may increase urinary oxalate, urate, or cystine concentrations, potentially contributing to stone formation in predisposed patients.
• Laboratory interference:
  High doses may cause false results on urine dipstick tests (eg, glucose, blood) and alter serum creatinine, bilirubin, or AST measurements.
• Exacerbation of hepatic injury:
  In dogs with copper-associated hepatopathy, ascorbic acid may worsen oxidative liver damage.

Overdose

Ascorbic acid has a wide safety margin in dogs and cats. Acute toxicity is rare, and most overdoses result in mild, self-limiting clinical signs.

• Large oral doses:
  May cause profuse diarrhea, dehydration, and electrolyte disturbances if fluid losses are not corrected.
• Urinary complications:
  Repeated excessive dosing may increase the risk of urolithiasis rather than causing acute toxicity.
• Toxic dose data:
  Single oral doses up to approximately 0.5 g/kg in dogs and 1 g/kg in cats have been reported to be well tolerated, with minimal adverse effects.
• Management:
  Treatment is supportive and includes discontinuation of supplementation, ensuring adequate hydration, and monitoring for gastrointestinal or urinary signs.

Key Notes

Practical clinical considerations for the rational use of ascorbic acid (vitamin C) in dogs and cats:

• Adjunct only:
  When used in dogs and cats, ascorbic acid should be considered an adjunctive therapy and not a primary treatment or antidote.
• Route matters:
  Clinically meaningful plasma concentrations are difficult to achieve with oral dosing; IV administration is required for higher systemic levels.
• Short-term use preferred:
  If indicated, use for the shortest effective duration to minimize gastrointestinal and urinary complications.
• Questionable benefit:
  Evidence supporting clinical benefit in small animals is limited; response should be reassessed frequently.
• Not a nutritional supplement:
  Ascorbic acid should not be added routinely to diets of dogs or cats with normal health status.
• Client counseling:
  Owners should be advised that “vitamin” does not equal “harmless,” and inappropriate dosing may cause adverse effects.